Sublocade/buprenorphine Cost, Side effects, Dosage, Uses Opioid use disorder

Sublocade/buprenorphine Cost, Side effects, Dosage, Uses Opioid use disorder. The FDA granted the approval of Sublocade to Indivior Inc.

US FDA approved drug Sublocade that contains buprenorphine as a active pharmaceutical ingredient for the treatment of moderate to severe opioid use disorder (OUD) in adult patients. This is the first once monthly injectable buprenorphine product. Availability of this drug is restricted to those pharmacies or hospital who are certified in REMS Program.

Opioid use disorder (OUD) is a condition that is directly related to  opioid use that causes clinically significant impairment or distress. Symptoms of opioid use disorder are strong desire to use opioids, enhanced tolerance rate and withdrawal syndrome in case opioids are abruptly stopped to administer. These symptoms may become severe if patient is misusing or overdosing opioids for longer period of time.

Opioids are basically medicinal products that are derived from synthetic or semi-synthetic sources for the relieving intense pain like trauma pain, Injuries, post operative pain or cancer pain. Supply of these products are kept under restriction due to their possible misuses or overdosing. Nalaxone is another important therapeutic drug used in case of opiod overdosing.

Sublocade Injection contains buprenorphine. Buprenorphine is a partial agonist at the mu receptor and antagonist at the kappa opioid receptor.

Sublocadebuprenorphine Cost, Side effects, Dosage, Uses Opioid use disorder

Sublocade/buprenorphine Side effects


Following side effects can be expected during the course of administration of this drug.

  • Nausea
  • Vomiting
  • Pain at injection site
  • Hypersensitivity
  • Rashes on skin
  • Fluctuation in the level of liver enzymes
  • Pruritis
  • Sleep disturbance

Sublocade/buprenorphine Uses/Prescribing Information


US FDA approved Sublocade for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosa buprenorphine containing product, followed by dose adjustment for a minimum of 7 days.

Sublocade/buprenorphine Dosage


Subcloade is injected in the abdominal area. Standard dosage frequency of Sublocade is 300 mg followed by 100 mg monthly maintenance doses. Maintenance doses might be increase depending upon the response rate and tolerance level of patient.

Sublocade/buprenorphine Cost


Sublocade/buprenorphine cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Ogivri/trastuzumab-dkst Cost, Side effects, Dosage, Uses for Certain Cancers

Ogivri/trastuzumab-dkst Cost, Side effects, Dosage, Uses for Certain Cancers. The FDA granted approval of Ogivri to Mylan GmbH. Herceptin was approved in September 1998 and is manufactured by Genentech, Inc.

US FDA approved new drug Ogivri that is a a biosimilar to Herceptin (trastuzumab) for the treatment of certain kind of metastatic cancers like metastatic breast cancer or metastatic stomach cancer. A biosimilar product is a pharmaceutical product that is similar to a reference product which already been approved by the US FDA and has no therapeutic differences in terms of safety, purity and potency.

Stomach cancer is also termed as gastric cancer. Early signs ans symptoms of stomach cancers are weight loss, loss of appetite, nausea and vomiting. In later stages patient may feel difficulty in swallowing and have blood in stool. Pain in upper abdominal area may also be a symptoms of gastric metastasis. In later stages it becomes difficult to treat stomach cancer because it spreads to other areas like bones, lungs, liver.

Breast cancer is one of the leading cause of death in females due to cancer. Initially, it appears as a lump inside the breast that growth with the passage of time and reaches to progressive metastatic stage. There are no obvious symptoms at initial stages that makes it hard to diagnose earlier. Later on patient may feel bone pain, swollen lymph nodes, fatigue, shortness of breath and mild fever in some cases also been reported.

This drug encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab products have been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2.

Ogivritrastuzumab-dkst Cost, Side effects, Dosage, Uses for Certain Cancers


Ogivri/trastuzumab-dkst Side effects


Following side effects were observed during clinical trials of this drug.

  • Headache
  • Nausea
  • Vomiting
  • Mild fever
  • Weakness
  • Rashes on body
  • Less white blood cells count
  • Less red blood cells count
  • Abdominal discomfort
  • Pain in abdomen
  • Edema like condition
  • Hypersensitivity
  • Changes in taste sensation


Ogivri/trastuzumab-dkst Uses/Prescribing Information


Ogivri/trastuzumab-dkst is a a biosimilar to Herceptin (trastuzumab) for the treatment of certain kind of metastatic cancers like metastatic breast cancer or metastatic stomach cancer. According to data provided by health authorities this drug should be avoided in pregnancy due to fetal abnormalities.

Ogivri/trastuzumab-dkst Dosage


This drug is administered via intravenous route.

It is dosage frequency is 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of  2 mg/kg as 30 minute IV infusions in case of Metastatic HER2-Overexpressing Breast Cancer.

Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks in case of Metastatic HER2-Overexpressing Gastric Cancer.


Ogivri/trastuzumab-dkst Cost


Ogivri/trastuzumab-dkst cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.